GSK Files Q2 Report Showing £8.4bn Sales and £1.9bn Savings Plan

GSK's 6-K restates second-quarter 2026 turnover of £8.4 billion, up 5%, alongside a three-year Accelerate Growth programme targeting £1.9 billion in annual savings by 2029.

Share
GSK reported second-quarter turnover of £8.4 billion across specialty medicines, vaccines and general medicines.
Source: Wikimedia